Advertisement

Migräne pp 19-76 | Cite as

Akuttherapie der Migräneattacke

  • Hans-Christoph Diener
Chapter
  • 61 Downloads
Part of the Optimierte Arzneimitteltherapie book series (ARZNEIMITTELTH.)

Zusammenfassung

Migräneattacken werden typischerweise von vegetativen Begleiterscheinungen wie Übelkeit und Erbrechen begleitet. Dabei kommt es zu einer Verringerung der Peristaltik, so daβ oral eingenommene Medikamente nur verzögert ins Duodenum und in tiefere Dünndarmabschnitte transportiert werden, wo sie dann auch verzögert resorbiert werden. Die Wirksamkeit oral eingenommener Medikamente, seien es Analgetika oder spezifische Migränemittel, hängt aber überwiegend von der Zeit ab, bis die maximale Konzentration im Serum erreicht wird. Dies erklärt, warum häufig Analgetika —allein eingenommen — nicht ausreichend wirksam sind.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Andersson PG, Hinge HH, Johansen O, Andersen CU, Lademann A, Gotzsche PC (1989) Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. Cephalalgia 9:29–32PubMedCrossRefGoogle Scholar
  2. Bannwarth B, Demotes-Mainard F, Schaeverbeke T, Labat L, Dehais J (1995) Central analgesic effects of aspirin-like drugs. Fund Clin Pharmacol 9:1–7CrossRefGoogle Scholar
  3. Bates D, Ashford E, Dawson R, Ensink F-BM, Gilhus NE, Olesen J, Pilgrim AJ, Shevlin P (1994) Subcutaneous sumatriptan during the migraine aura. Neurology 44:1587–1592PubMedGoogle Scholar
  4. Becker WJ, on behalf of the Study Group (1995) A placebo-controlled, dose-defining study of sumatriptan nasal spray in the acute treatment of migraine. Cephalagia 15 (Suppl 14): 239Google Scholar
  5. Brown EG, Endersby CA, Smith RN, Talbot JCC (1991) The safety and tolerability of sumatriptan: an overview. Eur Neurol 31:339–344PubMedCrossRefGoogle Scholar
  6. Brune K, Beck WS, Geisslinger G, Menzel-Soglowek S, Peskar BM, Peskar BA (1991) Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition. Experientia 47:257–261PubMedCrossRefGoogle Scholar
  7. Buzzi G, Moskowitz MA (1990) The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 99:202–206PubMedGoogle Scholar
  8. Buzzi G, Sakas DE, Moskowitz MA (1989) Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 165:251–258PubMedCrossRefGoogle Scholar
  9. Buzzi MG, Carter WB, Shimizu THH, Moskowitz MA (1991) Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 30:1193–1200PubMedCrossRefGoogle Scholar
  10. Buzzi MG, Moskowitz MA (1991) Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 11:165–168PubMedCrossRefGoogle Scholar
  11. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H (1991) Treatment of acute migraine with subcutaneous sumatriptan. JAMA 265:2831–2835PubMedCrossRefGoogle Scholar
  12. Chabriat H, Danchot J, Grippon P, Bousser MG (1994) Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. Cephalalgia 14:297–300PubMedCrossRefGoogle Scholar
  13. Connor HE, Fenjuk W, Beattie DT (1998) Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia im DruckGoogle Scholar
  14. Cumberbatch MJ, Hill RG, Hargreaves RJ (1997) Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 328:37–40PubMedCrossRefGoogle Scholar
  15. Dahlöf C (1993) Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 13:166–171PubMedCrossRefGoogle Scholar
  16. Dichgans J, Diener HC, Gerber WD, Verspohl EJ, Kukiolka H, Kluck M (1984) Analgetika-induzierter Dauerkopfschmerz. Dtsch med Wschr 109:369–373PubMedCrossRefGoogle Scholar
  17. Diener HC, Klein KB (1996) The first comparison of the efficacy and safety of 311C90 and sumatriptan in the treatment of migraine. Poster, 3rd European Headache Conference, SardiniaGoogle Scholar
  18. Dixon R, Gillotin C, Gibbens M, Posner J, Peck RW (1997a) The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. Br J Clin Pharmacol 3:273–281Google Scholar
  19. Dixon R, Warrander A (1997) The clinical pharmacokinetics of zolmitriptan. Cephalalgia 17:15–20PubMedCrossRefGoogle Scholar
  20. Dixon RM, Meire HB, Evans DH, Watt H, On N, Posner J, Rolan PE (1997b) Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers. Cephalalgia 17:639–646PubMedCrossRefGoogle Scholar
  21. Dowson AJ, on behalf of the Study Group (1996) An open, dose-titration study evaluating 25 mg, 50 mg and 100 mg doses of oral sumatriptan in the acute treatment of migraine. Poster, 2nd EFNS Congress, RomeGoogle Scholar
  22. Earl NL (1997) Zolmitriptan (311C90), a new acute treatment for migraine: an overview of safety. In: Oleson J, Tfelt-Hansen P (Hrsg.) Frontiers of Headache Research. Headache Treatment: Trial Methodology and New Drugs. Lippin-cott-Raven, New York, 267–272Google Scholar
  23. Edmeads JG, Millson DS (1997) Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5-HT1B/1D agonist. Cephalalgia 17:41–52PubMedGoogle Scholar
  24. Feniuk W, Humphrey PPA, Perren M (1989) The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs. Brit J Pharmacol 96:83–90Google Scholar
  25. Ferrari MD (1996) The clinical effectiveness of 311C90 in the acute treatment of migraine. Eur Neurol 36 (Suppl 2):4–7PubMedCrossRefGoogle Scholar
  26. Ferrari MD (1997) 311C90: Increasing the options for the therapy with effective acute antimigraine 5-HT1B/D receptor agonists. Neurology 48 (Suppl 3):21–24Google Scholar
  27. Gijsman H, Kramer MS, Sargent J, Tuchman M, Matzura-Wolfe D, Polis A, Teall J, Block G, Ferrari MD (1997) Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 17:647–651PubMedCrossRefGoogle Scholar
  28. Goadsby PJ, Edvinsson L (1994) Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 34: 394–399PubMedCrossRefGoogle Scholar
  29. Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183–187PubMedCrossRefGoogle Scholar
  30. Goadsby PJ, Gundlach AL (1991) Localization of 3H-Dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 29:91–94PubMedCrossRefGoogle Scholar
  31. Goadsby PJ, Hoskin KJ (1996) Inhibition of trigeminal neurons by intravenous administration of the serotonin (5-HT)lB/D receptor agonist zolmitriptan (311C90): Are brain stem sites therapeutic target in migraine? Pain 67:355–359PubMedCrossRefGoogle Scholar
  32. Goadsby PJ, Knight Y (1997) Inhibition of trigeminal neurones after intravenous administration of naratriptan trough an action at 5-hydroxytryptamine (5-HT1B/1D) receptors. Br J Pharmacol 122:918–922PubMedCrossRefGoogle Scholar
  33. Göbel H, Boswell D, Winter PDO, Crisp A (1997) A comparison of the efficacy and tolerability of naratriptan and sumatriptan among migraineurs with a history of frequent (50% of attacks) headache recurrence. Poster, VIIIth IHS Congress, Amsterdam.Google Scholar
  34. Göbel H, Ernst M, Jeschke J, Keil R, Weigle L (1992) Acetylsalicylic acid activates antinociceptive brain-stem reflex activity in headache patients and in healthy subjects. Pain 48:187–195PubMedCrossRefGoogle Scholar
  35. Gross MLP, Kay J, Turner AM, Jewsbury J, Cleal AL (1995) Long-term efficacy of subcutaneous sumatriptan using a novel self-injector. Headache 35:601–606PubMedCrossRefGoogle Scholar
  36. Hämäläinen ML, Hoppu K, Santavuori P (1997) Sumatriptan for migraine attacks in children: A randomized placebo-controlled study. Do children with migraine attacks respond to oral sumatriptan differently from adults? Neurology 48:1100–1103PubMedGoogle Scholar
  37. Havanka-Kanniainen H (1989) Treatment of acute migraine attack: ibuprofen and placebo compared. Headache 29:507–509PubMedCrossRefGoogle Scholar
  38. Humphrey PPA, Feniuk W, Motevalian M, Parsons A A, Whalley ET (1991) The vasoconstrictor action of sumatriptan on human isolated dura mater. In: Fozard JR, Saxena PR (Hrsg.) Serotonin: molecular biology, receptors and functional effects. Birkhäuser, Basel, 420–429Google Scholar
  39. Johnson ES, Ratcliffe DM, Wilkinson M (1985) Naproxen sodium in the treatment of migraine. Cephalalgia 5:5–10PubMedCrossRefGoogle Scholar
  40. Kaube H, Hoskin KL, Goadsby PJ (1993) Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 33:541–544PubMedCrossRefGoogle Scholar
  41. Kaube H, Hoskin KL, Goadsby PJ (1993) Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Cephalalgia 13 (Suppl 13):41Google Scholar
  42. Kaube H, May A, Diener HC, Pfaffenrath V (1994) Sumatriptan. BMJ 308:1573Google Scholar
  43. Kirch W, Ziegler A (1989) Pharmakologische Grundlagen der Anwendung von Dihydroergotamin. Neurologie Psychiatrie 2:43–48Google Scholar
  44. Klassen A, Elkind A AM, Webster C, Laurenza A, on behalf of the Naratriptan S2WA3001 Study Group (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Headache 37:630–645CrossRefGoogle Scholar
  45. Klassen AC, Gabriel H, Hobbs S, Woessner M (1995) Safety and efficacy of sumatriptan suppositories in the acute treatment of migraine attacks. Poster, VII. IHS Congress, TorontoGoogle Scholar
  46. Kunka RL, Hussey EK, Shaw S, Warner P, Aubert B, Richard I, Fowler PA, Pakes GE (1997) Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers. Cephalalgia 17:532–540PubMedCrossRefGoogle Scholar
  47. Lipton RB, Stewart WF (1997) Clinical applications of zolmitriptan (Zomig, 311C90). Cephalalgia 17 (Suppl 18):53–59PubMedGoogle Scholar
  48. Longmore J, Hargreaves RJ, Boulanger CM, Brown MJ, Desta B, Ferro A, Schofield WN, Taylor AA, Hill RG (1997) Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols. Funct Neurol 12:3–9PubMedGoogle Scholar
  49. MacGregor EA, Wilkinson M, Bancroft K (1993) Domperidone plus paracetamol in the treatment of migraine. Cephalalgia 13:124–127PubMedCrossRefGoogle Scholar
  50. Maclntyre PD, Bhargava B, hogg KJ, Gemmili JD, Hillis WS (1993) Effect of subcutaneous sumatriptan, a selective 5-HT1 agonist, on the systemic, pulmonary and coronary circulation. Circulation 87:401–405Google Scholar
  51. Martin G, Dixon R, Seaber E (1997) Preclinical and clinical pharmacology of Zolmitriptan (311C90): A novel antimigraine agent. In: Oleson J, Tfelt-Han-sen P (Hrsg.) Headache Treatment: Trial Methodology and New Drugs. Lippincott-Raven, New York, 257–262Google Scholar
  52. Martin GR (1996) Inhibition of the trigemino-vascular system with 5-HT1D agonist drugs: Selectively targeting additional sites of action. Eur.Neurol 36 (Suppl 2):13–18PubMedCrossRefGoogle Scholar
  53. Martin GR, Robertson AD, MacLennan SJ, Prentice DJ, Barret VJ, Buckingham J, Honey AC, Giles H, Moncada S (1997) Receptor specificity and trigeminovascular inhibitory actions of a novel 5-HT(lB/lD) receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol 2:157–164CrossRefGoogle Scholar
  54. Massiou H, on behalf of the Study Group (1996) A comparison of sumatriptan nasal spray 20 mg and intranasal dihydroergotamin in the acute treatment of migraine. Poster, 3rd European Headache Conference, SardiniaGoogle Scholar
  55. Mathew NT, Asgharnejad M, Peykamian M, Laurenza A, on behalf of the Naratriptan S2WA3003 Study Group (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. Neurology 49:1485–1490PubMedGoogle Scholar
  56. Monstadt I, on behalf of the Study Group (1995) The long-term tolerability, safety and efficacy of 25 mg sumatriptan suppositories in the acute treatment of migraine. Poster, VII. IHS Congress, TorontoGoogle Scholar
  57. Nebe J, Heier M, Diener HC (1995) Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia 15:531–535PubMedCrossRefGoogle Scholar
  58. O’Callaghan J, for the Study Group (1993) Long-term efficacy of subcutaneous sumatriptan using a novel self-injector. Cephalalgia 13 (Suppl 13): 161Google Scholar
  59. Parsons AA, Whalley ET, Feniuk W, Connor HE, Hunmphrey PPA (1989) 5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Brit J Pharmacol 96:434–449Google Scholar
  60. Patten JP (1991) Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study. J Neurol 238 (Suppl 1):S62–S65PubMedCrossRefGoogle Scholar
  61. Pearce I, Frank GJ, Pearce JMS (1983) Ibuprofen compared with paracetamol in migraine. Practitioner 227:465–467PubMedGoogle Scholar
  62. Pfaffenrath V on behalf of the Study Group (1996) A study comparing the efficacy, safety, and tolerability of oral sumatriptan 25 mg, 50 mg and 100 mg doses in the acute treatment of migraine. Poster, 2nd EFNS Congress, RomeGoogle Scholar
  63. Pilgrim AJ, Blakeborough P (1994) The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev Contemp Pharmacother 5: 95–309Google Scholar
  64. Rapoport AM, Ramadan NM, Adelmann JU, Mathew NT, Elkind AH, Kudrow DB, Earl NL, on behalf of the 017 Clinical Trial Study Group (1997) Optimizing the dose of zolmitriptan (Zomig 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose-finding study. Neurology 49:1210–1218PubMedGoogle Scholar
  65. Rolan P (1997) Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia 17:21–27PubMedGoogle Scholar
  66. Rosenkranz S, Deutsch HJ, Erdmann E (1997) “Saint Anthony’s Fire”: Ergotamin-induzierte Gefäβspasmen als Ursache akuter ischämischer Syndrome. Dtsch Med Wochenschr 14:450–454CrossRefGoogle Scholar
  67. Ross-Lee LM, Eadie MJ, Heazlewood V, Bochner F, Tyrer JH (1983) Aspirin pharmacokinetics in migraine. The effect of metoclopramide. Eur J Clin Pharmacol 24:777–785PubMedCrossRefGoogle Scholar
  68. Ryan R, Elkind A, Baker CC, Mullican W, DeBussy S, Asgharnejad M (1997) Sumatriptan nasal spray for the acute treatment of migraine. Neurology 49:1225–1230PubMedGoogle Scholar
  69. Saito K, Markowitz S, Moskowitz MA (1988) Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol 24:732–737PubMedCrossRefGoogle Scholar
  70. Salonen R on behalf of the Study Group (1996) Patient preference among 25 mg, 50 mg and 100 mg oral doses of sumatriptan. Poster, 2nd EFNS Congress, RomeGoogle Scholar
  71. Salonen R, Ashford E, Dahlöf C, Dawson R, Gilhus NE, Lüben V, Noronha D, Warter J, for the International Study Group (1994) Intranasal sumatriptan for the acute treatment of migraine. J Neurol 241:463–469PubMedCrossRefGoogle Scholar
  72. Schoenen J, Sawyer J (1997) Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. Cephalalgia 17 Suppl 18:28–40PubMedGoogle Scholar
  73. Sciberras DG, Polvino WJ, Gertz BJ, Cheng H, Stepanavage M, Wittreich J, Olah T, Edwards M, Mant T (1997) Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. Br J Clin Pharmacol 43:49–54PubMedCrossRefGoogle Scholar
  74. Seaber E, On N, Dixon RM, Gibbens M, Leavens WJ, Liptrot J, Chittick G, Posner J, Rolant PE, Peck RW (1997) The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br J Clin Pharmacol 43:579–587PubMedCrossRefGoogle Scholar
  75. Shepheard SL, Williamson DJ, Beer MS, Hill RG, Hargreaves RJ (1997) Differential effects of 5-HT1B/D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology 36:525–533CrossRefGoogle Scholar
  76. Solomon GD, Cade RK, Klapper JA, Earl NL, Saper JR, Ramadan NM, on behalf of the 042 Clinical Trial Study Group (1997) Clinical efficacy and tolerability of 2,5 mg zolmitriptan for the acute treatment of migraine. Neurology 49:1219–1225PubMedGoogle Scholar
  77. Tansey MJB, Pilgrim AJ, Lloyd K (1993) Sumatriptan in acute treatment of migraine. J Neurol Sci 114:109–116PubMedCrossRefGoogle Scholar
  78. Tfelt-Hansen P, Henry P, Mulder LJ, Schaeldewaert RG, Schoenen J, Chazot G (1995) The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 346:923–926PubMedCrossRefGoogle Scholar
  79. Tfelt-Hansen P, Olesen J (1984) Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 4:107–111PubMedCrossRefGoogle Scholar
  80. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group (1991) A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 31:314–322CrossRefGoogle Scholar
  81. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group (1992) A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 32:177–184CrossRefGoogle Scholar
  82. The Oral Sumatriptan Dose-Defining Study Group (1991) Sumatriptan — an oral dose- defining study. Eur Neurol 31:300–305CrossRefGoogle Scholar
  83. The Oral Sumatriptan International Multiple-Dose Study Group (1991) Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 31:306–313CrossRefGoogle Scholar
  84. The Subcutaneous Sumatriptan International Study Group (1991) Treatment of migraine attacks with sumatriptan. N Engl J Med 325:316–321CrossRefGoogle Scholar
  85. The Sumatriptan Auto-Injector Study Group (1991) Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol 31:323–331CrossRefGoogle Scholar
  86. Touchon J, Bertin L, Pilgrim AJ, Ashford E, Bès A (1996) A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 47:361–365PubMedGoogle Scholar
  87. Visser (1997) Pharmacologic profile and clinical efficacy of rizatriptan. Vortrag VIII. IHS Congress, AmsterdamGoogle Scholar
  88. Visser WH, for the Study Group (1993) Does a combined regimen of subcutaneous followed by oral sumatriptan prevent headache recurrence. Cephalalgia 13, Suppl. 13:189Google Scholar
  89. Visser WH, Jaspers NMWH, de Vriend RHM, Ferrari MD (1996) Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 16:264–269PubMedCrossRefGoogle Scholar
  90. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD, for the Dutch/US Rizatriptan Study Group (1997) Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Arch Neurol 53:1132–1137Google Scholar
  91. Volans GN (1975) The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol 2:57–63PubMedGoogle Scholar
  92. Weiller C, May A, Limmroth V, Jüptner M, Kaube H, van Schayck R, Coenen HH, Diener HC (1995) Brain stem activation in spontaneous human migraine attacks. Nature Medicine 1:658–660PubMedCrossRefGoogle Scholar
  93. Wilkinson M, Pfaffenrath V, Schoenen J, Diener HC, Steiner T (1995) Migraine and cluster headache — their management with sumatriptan: a critical rewiew of the current clinical experience. Cephalalgia 15:337–357PubMedCrossRefGoogle Scholar
  94. Williamsen DJ, Shepheard SL, Hill RG, Hargreaves RJ (1997) The novel anti-migraine agent rizatriptan inhibtis neurogenic durai vasodilation and extravasation. Eur J Pharmacol 328:61–64CrossRefGoogle Scholar
  95. Zagami AS, for the 311C90 Long-Term Study Group (1997) 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. Neurology 48 (Suppl 3):S25–S28Google Scholar
  96. Zschiedrich M, Heidrich H, Dienes HP (1985) Ergotismus: Epidemiologie, Pathogenese, Histomorphologie, Diagnostik und Therapie. Med Klinik 80:721–727Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • Hans-Christoph Diener
    • 1
  1. 1.Klinik und Poliklinik für NeurologieUniversität EssenEssenDeutschland

Personalised recommendations